IGCS20_1189

30

RISK FACTORS ASSOCIATED WITH INCREASING INCIDENCE OF UTERINE CANCER AFTER CORRECTING FOR HYSTERECTOMY

¹C Liao, ²K Tran, ²M Richardson*, ³K Darcy, ⁴C Tian, ⁵CA Hamilton, ⁴L Maxwell, ⁶A Mann, ⁷DS Kapp, ⁶JK Chan. ¹Kaohsiung Veterans General Hospital, Taiwan; ²University of California, Los Angeles, USA; ³Virginia Commonwealth University School of Medicine Inova Fairfax Campus, USA; ⁴Walter Reed National Military Medical Center, USA; ⁵Inova Schar Cancer Institute, USA; ⁶Palo Alto Medical Foundation, California Pacific Medical Center, Sutter Health, USA; ⁷Stanford University School of Medicine, USA

10.1136/ijgc-2020-IGCS.30

Objective To evaluate the demographic factors associated with the increase in incidence of uterine cancer after correcting for hysterectomy.

Methods From 2001–2016, incidence rates of uterine cancers (epithelial carcinoma and sarcomas) were estimated from United States Cancer Statistics after correcting for hysterectomy prevalence based on Behavioral Risk Factor Surveillance System data. SEER*Stat and Joinpoint regression were used to calculate incidence rate (per 100,000) and average annual percent change (AAPC).

Results Of 720,984 patients, 78% White, 10% Black, 8% Hispanic, and 3% Asian/Pacific-Islander. After correcting for hysterectomy, the estimated incidence increased from 27.1 to 42/100,000 women. Over 15 years, the incidence increased from

Abstract 30 Figure 1

Abstract 30 Figure 2

40.8 to 42.9 with an annual percent increase (AAPC) of 0.5% per year ($p < 0.05$). The 65–69 year old group had the highest incidence (185.4). With respect to race, the highest baseline incidence was in Blacks at 49.5 that increased 2.3% per year (AAPC). Whites had an incidence of 43.6 with an annual percent increase of only 0.4%. The Hispanics had an incidence of 35.0 (AAPC=1.1%), then Asians incidence 24.0 (AAPC=1.3%). The intersectionality of age and race showed that the group with the highest risk was 65–69 year old and Black with an incidence of 281.1 (AAPC=2.3%).

Conclusion The intersectionality of age and race found age 65–69 Black women with the highest incidence of uterine cancer with a six-fold increase compared to the general population, using hysterectomy-corrected data. Further studies are warranted to determine potential genetic, social-determinant, or environment exposures to explain these findings.

IGCS20_1179

31 SURVIVAL OUTCOMES IN ENDOMETRIAL CANCER PATIENTS HAVING LYMPHADENECTOMY, SENTINEL NODE MAPPING FOLLOWED BY LYMPHADENECTOMY AND SENTINEL NODE MAPPING ALONE: LONG-TERM RESULTS OF A PROPENSITY-MATCHED ANALYSIS

¹G Bogani*, ¹C Pinelli, ¹A Ditto, ²J Casarin, ²F Ghezzi, ¹F Raspagliesi. ¹Fondazione IRCCS Istituto Nazionale Dei Tumori, Italy; ²University of Insubria, Italy

10.1136/ijgc-2020-IGCS.31

Objective Sentinel node mapping (SLNM) has replaced lymphadenectomy for staging surgery in apparent early-stage endometrial cancer (EC). Here, we evaluate long-term survival of three different approaches of nodal assessment in EC.

Methods This is a multi-institutional retrospective study evaluating long-term outcomes (at least 3 years) of patients having lymphadenectomy, SLNM followed by lymphadenectomy and SLNM alone. We applied a propensity-matched algorithm. Survival outcomes were assessed using Kaplan-Meier and Cox proportional hazard models

Results Applying a propensity score matching algorithm we selected 180 patients having SLNM (90 SLNM vs. 90 SLNM followed by lymphadenectomy). Additionally, a control group of 180 patients having lymphadenectomy was selected. Overall, 10% of patients were diagnosed with positive nodes. Low volume disease was observed in 16 cases (5 micrometastasis and 11 isolated tumor cells). Patients having SLNM followed by lymphadenectomy had a higher possibility to be diagnosed with a stage IIIC disease in comparison to lymphadenectomy alone ($p=0.02$); while we did not observe a difference in the diagnostic value of SLNM followed by lymphadenectomy and SLNM ($p=0.389$). Median follow-up time was 69 (7–206) months. There were no statistical differences in terms of disease-free ($p=0.570$, log-rank test) and overall survival ($p=0.911$, log-rank test); Similarly, they did not impact on survival outcomes after stratification by low, intermediate and high-risk patients.

Conclusions Our study highlighted that SLNM provides similar long-term oncologic outcomes than lymphadenectomy, even in high-risk patients. Further evidence is warranted to assess the prognostic value of low volume disease detected by ultrastaging in patients following SLNM.

Oral Poster – TAPED

Oral Featured Posters – Pre-Recorded

IGCS20_1018

32 DEVELOPMENT OF A TRIAGE TOOL INCLUDING HE4, D-DIMER, AND FIBRINOGEN FOR THE ASSESSMENT OF WOMEN PRESENTING WITH PELVIC MASSES

K McKendry*, S Duff, S O'Toole. Saint James's Hospital, Ireland

10.1136/ijgc-2020-IGCS.32

Introduction 10% of pre- and 20% of post-menopausal women presenting with a pelvic mass will receive a diagnosis of ovarian cancer (OC). Algorithms are being formulated to improve on CA125 alone in classifying women presenting with pelvic masses as high or low risk for OC. The aim of this study was to evaluate novel biomarkers HE4, the Risk of Ovarian Malignancy Algorithm, the Risk of Malignancy Index I and II, D-dimer, and fibrinogen, alone or in combination, compared to CA125.

Methods Pre-operative serum samples were collected from 274 patients undergoing primary debulking surgery in an Irish tertiary referral centre. Logistic regression models and ROC curves were fitted for each biomarker alone and in combination. The partial area under the curve (pAUC) in the 90–100% specificity range was determined. Biomarker cutoffs were calculated at 90–100% and 98% specificity.

Results There were 89 pre- and 185 post-menopausal women, consisting of 144 benign, 41 borderline, and 89 OC cases. In the premenopausal group, no biomarker(s) outperformed CA125 (AUC 0.73; 95% CI 0.63–0.84). In the postmenopausal group, HE4 + D-dimer + fibrinogen outperformed CA125 alone (AUC 0.83 versus 0.77, $p=0.023$). HE4 + D-dimer had the highest pAUC at 72.59 (95% CI 66.16–79.72) and outperformed CA125 ($p=0.001$).

Conclusion The addition of biomarker(s) to CA125 does not increase OC detection in premenopausal women. A novel biomarker panel (HE4 + D-dimer + fibrinogen) improved the diagnostic accuracy of CA125 alone in postmenopausal women and could aid in the preoperative triaging of pelvic masses.

IGCS20_1067

33 MOLECULAR SUBTYPE DIAGNOSIS OF ENDOMETRIAL CARCINOMA: COMPARISON OF NGS PANEL AND PROMISE CLASSIFIER

¹J Huvila*, ¹K Orte, ¹P Vainio, ²T Mettälä, ²T Joutsinimi, ²S Hietanen. ¹Department of Pathology, University of Turku and Turku University Hospital, Finland; ²Department of Gynecology and Obstetrics, University of Turku and Turku University Hospital, Finland

10.1136/ijgc-2020-IGCS.33

Objectives The molecular classification of endometrial carcinoma (EC) is taking the diagnosis on EC to a more comprehensive level and will aid to better identify those patients whose disease is likely to behave differently than predicted when using traditional risk stratification. We are transitioning